Malignant transformation and new primary tumours after therapeutic radiation for benign disease: Substantial risks in certain tumour prone syndromes

D. Gareth R Evans, J. M. Birch, R. T. Ramsden, S. Sharif, M. E. Baser

    Research output: Contribution to journalArticlepeer-review

    Abstract

    In recent years the use of radiation treatment for benign tumours has increased with the advent of stereotactic delivery and, in particular, single high dose gamma knife therapy. This has been particularly true for benign CNS (central nervous system) tumours such as vestibular schwannoma, meningioma, pituitary adenoma, and haemangioblastoma. While short term follow up in patients with isolated tumours suggests this treatment is safe, there are particular concerns regarding its use in childhood and in tumour predisposing syndromes. We have reviewed the use of radiation treatment in these contexts with particular regard to malignant transformation and new tumour induction. This review indicates that much more caution is warranted regarding the use of radiation treatment for benign tumours in childhood and in tumour prone conditions such as the neurofibromatoses.
    Original languageEnglish
    Pages (from-to)289-294
    Number of pages5
    JournalJournal of Medical Genetics
    Volume43
    Issue number4
    DOIs
    Publication statusPublished - Apr 2006

    Keywords

    • radiotherapy: Basal Cell Nevus Syndrome
    • Cell Transformation, Neoplastic
    • Humans
    • radiotherapy: Li-Fraumeni Syndrome
    • etiology: Neoplasms
    • epidemiology: Neoplasms, Radiation-Induced
    • radiotherapy: Neurofibromatoses
    • adverse effects: Radiotherapy
    • radiotherapy: Retinoblastoma
    • Risk Factors
    • Syndrome
    • radiotherapy: von Hippel-Lindau Disease

    Fingerprint

    Dive into the research topics of 'Malignant transformation and new primary tumours after therapeutic radiation for benign disease: Substantial risks in certain tumour prone syndromes'. Together they form a unique fingerprint.

    Cite this